Last reviewed · How we verify
NCT00888680
Double-blind, Placebo-controlled Study of BGC20-1531 in Migraine
Phase 2 trial testing BGC20-1531 in Migraine. Withdrawn.
Quick facts
| Lead sponsor | Boston Scientific Corporation |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | treatment |
| Sites | 4 locations across Denmark, United Kingdom, Norway |
Drugs / interventions tested
- BGC20-1531 — full drug profile →
- Lactose (Lactose) — full drug profile →
Conditions studied
- Migraine — all drugs for Migraine →
Sponsor
Boston Scientific Corporation — full company profile →
Who can join
Adults 18 to 65, any sex, with Migraine. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is being conducted to explore the safety and effectiveness of a new chemical entity, BGC20-1531, in subjects with a history of migraine. In this study subjects will treat a total of three migraine attacks with two different doses of BGC20-1531 and placebo, with at least one week wash out period between doses.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Roles of EP Receptors in the Regulation of Fluid Balance and Blood Pressure.
Wang L, Wu Y, Jia Z, Yu J, et al · · 2022 · cited 11× · PMID 35813612 · DOI 10.3389/fendo.2022.875425
Verify or expand the search:
- PubMed search for NCT00888680
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Migraine
Currently open trials in the same condition.
- NCT07419607 — MIGRAFIT: Evaluating a Group Therapy Program Combining Physical Activity, Progressive Muscle Relaxation and Psychoeducat · NA · recruiting
- NCT07487701 — Migraine Prevention With the Remote Electrical Neuromodulation (REN) Wearable: A Real-world Evidence Study · NA · active not recruiting
- NCT07343427 — Impact of GON PRF on Central Sensitization in Migraine Patients · NA · active not recruiting
- NCT07336056 — Nerivio Efficacy Under High-Frequency Use · Phase 4 · active not recruiting
- NCT07385755 — Desvenlafaxine for Preventive Treatment of Frequent Migraines · NA · active not recruiting
Other Boston Scientific Corporation trials
Trials by the same sponsor.
- NCT07458243 — Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT · not yet recruiting
- NCT07458217 — Combined CM and STN Stimulation for Motor Epilepsy · NA · not yet recruiting
- NCT07276815 — OverStitch NXT Endoscopic Suture System · NA · not yet recruiting
- NCT07353710 — A Study on the Acquisition of 2D ICE Images With the CHORUS IDx System in Subjects Undergoing an Ablation Procedure · NA · not yet recruiting
- NCT07195708 — Orbera365 Intragastric Balloon System (Abbreviated as'Orbera365') · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00888680 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston Scientific Corporation
- Last refreshed: 3 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00888680.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing